Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update
Gamgertamig poster accepted for presentation at the 2026 ASH 1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”